[{"orgOrder":0,"company":"Cenexi","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"CoVepiT","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cenexi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cenexi \/ OSE Immunotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Cenexi \/ OSE Immunotherapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Cenexi

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : Cenexi will manufacture and process the peptides, produce the sterile emulsion and package the clinical batches of CoVepiT being used in the ongoing Phase 1 clinical trial and potentially for further clinical phases, subject to positive results of the Ph...

                          Brand Name : OSE13E

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          June 30, 2021

                          Lead Product(s) : CoVepiT

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : OSE Immunotherapeutics SA

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank